Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 8/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | PDE1A | P54750 | 1/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25876283 | 0.87 | PDE1A (0.44) | PDE2APDE1APDE1BPDE1C | |
| SCHEMBL17926576 | 0.83 | HSP90AA1 (0.39) | PDE2AKMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL25875949 | 0.83 | ADORA3 (0.42) | PDE2AKMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL25876313 | 0.81 | CYP17A1 (0.43) | PDE2ACYP1A2 | |
| SCHEMBL25875979 | 0.81 | PDE2A (0.35) | PDE2A | |
| SCHEMBL24393156 | 0.78 | PDE2A (0.62) | PDE2AKMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL25876067 | 0.77 | PDE1A (0.41) | PDE2AKMT2APDE1APDE1BPDE1C | |
| SCHEMBL25875898 | 0.73 | MAPT (0.33) | PDE2A | |
| SCHEMBL2786539 | 0.72 | PDE1A (0.42) | PDE2AKMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29175001 | 0.70 | KDM4E (0.42) | PDE2AKMT2APDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | TYK MEDICINES, INC. (CN) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234954-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | RET, ROR1, FGFR3 | PDE2A 1000/4885KMT2A 585/4885CYP1A2 3026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.